India Now Has Dr. Rajeev Singh Raghuvanshi As The New Drugs Controller General Of India

India Now Has Dr. Rajeev Singh Raghuvanshi As The New Drugs Controller General Of India

Indian Pharmacopoeia Commission secretary-cum-scientific director Dr. Rajeev Singh Raghuvanshi was appointed the new Drugs Controller General of India (DCGI) on Wednesday.

The ACC order said that "The Appointments Committee of the Cabinet has consented to the proposal for appointing Dr. Rajeev Singh Raghuvanshi as the Drugs Controller (India) at the Central Drugs Standard Control Organization (CDSCO)." It also mentions that his appointment will be in effect from the date he accepts the charge till he gains the age of superannuation on February 28, 2025, or until the next orders, whichever is earlier.

The DCGI governs the Central Drugs Standard Control Organisation (CDSCO), which is responsible for guaranteeing quality drug supply throughout the country; and holds the authority to give approval to new drugs and regulate clinical trials. 

Dr. Rajeev completed his bachelor's and Master's studies at IIT-BHU, Varanasi, and his Ph.D. at New Delhi's National Institute of Immunology. After serving seven years at the National Institute of Immunology, he entered the leading Indian multinational pharmaceutical company Ranbaxy Laboratories Ltd., where he worked for 12 years. Later, he moved to Dr. Reddy's Laboratories Ltd, Hyderabad, serving again for 11 glorious years. 

Dr. Raghuvanshi has expertise in dosage form design and development, mainly in pharmaceutical innovation. He has been developing various kinds of products like oral solids, oral liquids, topicals, injections, nasal sprays, auto-injectors, sublingual, mouth dissolve, extended-release, and delayed-release for multinational markets.

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks